Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2014

Open Access 01-12-2014 | Research article

Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis

Authors: Lei Wang, Li Zhang, Haobo Pan, Songlin Peng, Minmin Lv, William Weijia Lu

Published in: BMC Musculoskeletal Disorders | Issue 1/2014

Login to get access

Abstract

Background

The precise etiology of knee osteoarthritis (KOA) pain remains highly controversial and there is no known effective treatment. Due to the known and suggested effects of neuropeptide Y (NPY) on pain, we have sought to investigate the relationship between the concentration of NPY in synovial fluid of knee, pain of KOA, and structural severity of KOA.

Methods

One hundred KOA patients and twenty healthy participants (control group) were recruited. The pain and the radiographic grade of KOA were assessed separately by Hideo Watanabe’s pain score and Tomihisa Koshino’s scoring system. Synovial fluid of knee from all participants was collected with arthrocentesis. Radioimmunoassay was used to examine the concentration of NPY in synovial fluid of knee.

Results

Concentrations of NPY in synovial fluid were significantly higher in KOA patients (124.7 ± 33.4 pg/mL) compared with controls (64.8 ± 26.3 pg/mL) (p = 0.0297). According to Hideo Watanabe’s pain score, 100 KOA patients were divided into 5 subgroups: no pain (n = 12), mild pain (n = 25), moderate pain (n = 37), strong pain (n = 19) and severe pain (n = 7). Within the KOA group, significantly higher concentrations of NPY were found in each subgroup as pain intensified (no pain 81.4 ± 11.7 pg/mL, mild pain 99.1 ± 23.2 pg/mL, moderate pain 119.9 ± 31.5 pg/mL, strong pain 171.2 ± 37.3 pg/mL and severe pain 197.3 ± 41.9 pg/mL). Meanwhile, according to Tomihisa Koshino’s scoring system, 100 KOA patients were divided into 3 subgroups: early stage (n = 30), middle stage (n = 53), advanced stage (n = 17). Concentrations of NPY in middle and advanced stage groups of KOA patients were significant higher than early stage group of KOA patients (early stage 96.4 ± 27.1 pg/mL, middle stage 153.3 ± 16.9 pg/mL, advanced stage 149.5 ± 36.7 pg/mL) (p = 0.0163, p = 0.0352). Concentrations of NPY in advanced stage group of KOA patients has no significant difference compare with middle stage group of KOA patients (p = 0. 2175).

Conclusions

This study demonstrated the presence and variation of concentrations of NPY in the KOA joint fluid, suggesting a role for NPY as a putative regulator of pain transmission and perception in KOA pain.
Appendix
Available only for authorised users
Literature
1.
WHO: The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser. 2003, 919: 1-218.
2.
Felson DT: The epidemiology osteoarthritis. Osteoarthritis. Edited by: Brandt KD, Doherty M, Lohmander LS. 2003, Oxford, England: Oxford University Press, 9-16.
3.
Le Pen C, Reygrobellet C, Gerentes I: Financial cost of osteoarthritis in France. The “COART” France study. Joint Bone Spine. 2005, 72: 567-570. 10.1016/j.jbspin.2005.01.011.CrossRefPubMed
4.
Hadler NM: Osteoarthritis as a public health problem. Clin Rheum Dis. 1985, 11 (2): 175-185.PubMed
5.
Peat G, McCarney R, Croft P: Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis. 2001, 60: 91-97. 10.1136/ard.60.2.91.CrossRefPubMedPubMedCentral
6.
Simon LS: Osteoarthritis: a review. Clin Cornerstone. 1999, 2: 26-37. 10.1016/S1098-3597(99)90012-1.CrossRefPubMed
7.
Felson DT: The epidemiology of osteoarthritis: prevalence and risk factors. Osteoarthritic disorders. Edited by: Kuettner KE, Goldberg CH. 1995, Rosemont (IL): American Academy of Orthopaedic Surgeons, 13-24.
8.
9.
10.
Dieppe PA, Lohmander LS: Pathogenesis and management of pain in osteoarthritis. Lancet. 2005, 365: 965-973. 10.1016/S0140-6736(05)71086-2.CrossRefPubMed
11.
Brandt KD, Dieppe P, Radin EL: Etiopathogenesis of osteoarthritis. Rheum Dis Clin North Am. 2008, 34: 531-559. 10.1016/j.rdc.2008.05.011.CrossRefPubMed
12.
Jason J, Mc D, Lisa W, Zongming L: Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis. Pain. 2006, 123: 98-105. 10.1016/j.pain.2006.02.015.CrossRef
13.
Cerda-Reverter JM, Larhammar D: Neuropeptide Y family of peptides: Structure, anatomical expression, function, and molecular evolution. Biochem Cell Biol. 2000, 78: 371-392.CrossRefPubMed
14.
Duggan AW, Hope PJ, Lang CW: Microinjection of neuropeptide Y into the superficial dorsal horn reduces stimulus-evoked release of immunoreactive substance P in the anaesthetized cat. Neuroscience. 1991, 44: 733-740. 10.1016/0306-4522(91)90092-3.CrossRefPubMed
15.
Munglani R, Hudspith MJ, Hunt SP, Hunt SP: The therapeutic potential of neuropeptide Y. Analgesic, anxiolytic and antihypertensive. Drugs. 1996, 52 (Hunt, S.P): 371-389.CrossRefPubMed
16.
Silva AP, Cavadas C, Grouzmann E: Neuropeptide Y and its receptors as potential therapeutic drug targets. Clin Chim Acta. 2002, 326: 3-25. 10.1016/S0009-8981(02)00301-7.CrossRefPubMed
17.
Pedrazzini T, Pralong F, Grouzmann E: Neuropeptide Y: The universal soldier. Cell Mol Life Sci. 2003, 60: 350-377. 10.1007/s000180300029.CrossRefPubMed
18.
Bedoui S, Kawamura N, Straub RH, Pabst R, Yamamura T, von Horsten S: Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol. 2003, 134: 1-11. 10.1016/S0165-5728(02)00424-1.CrossRefPubMed
19.
Bedoui S, Miyake S, Lin Y, Miyamoto K, Oki S, Kawamura N, Beck-Sickinger A, von Horsten S, Yamamura T: Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J Immunol. 2003, 171: 3451-3458. 10.4049/jimmunol.171.7.3451.CrossRefPubMed
20.
Taiwo OB, Taylor BK: Antihyperalgesic effects of intrathecal neuropeptide Y during inflammation are mediated by Y1 receptors. Pain. 2002, 96: 353-363. 10.1016/S0304-3959(01)00481-X.CrossRefPubMed
21.
Taylor BK, Dadia N, Yang CB, Krishnan S, Badr M: Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Inflammation. 2002, 26: 121-127. 10.1023/A:1015500531113.CrossRefPubMed
22.
Ma W, Bisby MA: Partial and complete sciatic nerve injuries induce similar increases of neuropeptide Y and vasoactive intestinal peptide immunoreactivities in primary sensory neurons and their central projections. Neuroscience. 1998, 86: 1217-1234. 10.1016/S0306-4522(98)00068-2.CrossRefPubMed
23.
Ossipov MH, Zhang ET, Carvajal C, Gardell L, Quirion R, Dumont Y, Lai J, Porreca F: Selective mediation of nerve injury-induced tactile hypersensitivity by neuropeptide Y. J Neurosci. 2002, 22: 9858-9867.PubMed
24.
Tatemoto K: Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci U S A. 1982, 79 (18): 5485-5489. 10.1073/pnas.79.18.5485.CrossRefPubMedPubMedCentral
25.
Lundberg JM: Terenius L, H6kfelt T., Martling C.-R., Tatemoto, K., Mutt V., Polak J., Bloom S., Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 1982, 116: 477-480. 10.1111/j.1748-1716.1982.tb07171.x.CrossRefPubMed
26.
Ichikawa H, Wakisaka S, Matsuo S, Akai M: Peptidergic innervation of the temporomandibular disk in the rat. Experientia. 1989, 45: 303-304. 10.1007/BF01951817.CrossRefPubMed
27.
Taylor BK, Abhyankar SS, Vo NT, Kriedt CL, Churi SB, Urban JH: Neuropeptide Y acts Y1 receptors in the rostral ventral medulla to inhibit neuropathic pain. Pain. 2007, 131: 83-95. 10.1016/j.pain.2006.12.018.CrossRefPubMedPubMedCentral
28.
Ji RR, Zhang X, Wiesenfeld-Hallin Z, Hokfelt T: Expression of neuropeptide Y and neuropeptide Y (Y1) receptor mRNA in rat spinal cord and dorsal root ganglia following peripheral tissue inflammation. J Neurosci. 1994, 14: 6423-6434.PubMed
29.
Hokfelt T, Brumovsky P, Shi T, Pedrazzini T, Villar M: NPY and pain as seen from the histochemical side. Peptides. 2007, 28: 365-372. 10.1016/j.peptides.2006.07.024.CrossRefPubMed
30.
Gibson SJ, Polak JM, Allen JM, Adrian TE, Kelly JS, Bloom SR: The distribution and origin of a novel brain peptide, neuropeptide Y, in the spinal cord of several mammals. J Comp Neurol. 1984, 227: 78-91. 10.1002/cne.902270109.CrossRefPubMed
31.
Porreca F, Ossipov MH, Gebhart GF: Chronic pain and medullary descending facilitation. Trends Neurosci. 2002, 25: 319-325. 10.1016/S0166-2236(02)02157-4.CrossRefPubMed
32.
Ren K, Dubner R: Descending modulation in persistent pain: An update. Pain. 2002, 100: 1-6. 10.1016/S0304-3959(02)00368-8.CrossRefPubMed
33.
Just S, Pawlak M, Heppelmann B: Responses of fine primary afferent nerve fibres innervating the rat knee joint to defined torque. J Neurosci Methods. 2000, 103: 157-162. 10.1016/S0165-0270(00)00310-1.CrossRefPubMed
34.
Schaible HG, Schmidt RF: Responses of fine medial articular nerve afferents to passive movements of knee joints. J Neurophysiol. 1983, 49: 1118-1126.PubMed
35.
36.
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, Howell D, Kaplan D, Koopman W, Longley S, Mankin H, McShane DJ, Medsger T, Meenan R, Mikkelsen W, Moskowitz R, Murphy W, Rothschild B, Segal M, Sokoloff L, Wolfe F: Development of criteria for the classification and reporting of osteoarthritis. Arthritis Rheum. 1986, 29: 1039-1049. 10.1002/art.1780290816.CrossRefPubMed
37.
Hideo Watanabe: Rihabiritēshon shinryō hikkei. 1982, Tōkyō: Ishiyaku Shuppan
38.
Koshino T, Yoshida T, Ara Y, Saito I, Saito T: Fifteen to twenty-eight years’ follow-up results of high tibial valgus osteotomy for osteoarthritic knee. Knee. 2004, 11: 439-444. 10.1016/j.knee.2004.03.005.CrossRefPubMed
39.
Selvon F: St. Clair, Carlos Higuera, Viktor Krebs, Nabil A. Tadross, Jerrod Dumpe, Wael K. Barsoum. Hip and Knee Arthroplasty in the Geriatric Population. Clin Geriatr Med. 2006, 22: 515-533. 10.1016/j.cger.2006.04.004.CrossRef
40.
Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E: Immunoreactive tachykinins, calcitonin gene-related peptide and neuropeptide Y in human synovial fluid from inflamed joints. Neurosci Lett. 1989, 100: 326-330. 10.1016/0304-3940(89)90707-6.CrossRefPubMed
41.
Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E: Concentration of substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol. 1991, 20: 326-335. 10.3109/03009749109096808.CrossRefPubMed
42.
Lethbridge-Cejku M, Scott WW, Reichle R, Ettinger WH, Zonderman A, Costa P, Plato CC, Tobin JD, Hochberg MC: Association of radiographic features of osteoarthritis of the knee with knee pain: data from the Baltimore Longitudinal Study of Aging. Arthritis Care Res. 1995, 8: 182-188. 10.1002/art.1790080311.CrossRefPubMed
43.
Dieppe PA: Relationship between symptoms and structural change in osteoarthritis. What are the important targets for osteoarthritis therapy?. J Rheumatol Suppl. 2004, 70: 50-53.PubMed
44.
Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF: The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1987, 30: 914-918. 10.1002/art.1780300811.CrossRefPubMed
45.
Hannan MT, Felson DT, Pincus T: Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol. 2000, 27: 1513-1517.PubMed
46.
Claessens AA, Schouten JS, van den Ouweland FA, Valkenburg HA: Do clinical findings associate with radiographic osteoarthritis of the knee?. Ann Rheum Dis. 1990, 49: 771-774. 10.1136/ard.49.10.771.CrossRefPubMedPubMedCentral
47.
Bedson J, Croft P: The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008, 9: 116-10.1186/1471-2474-9-116.CrossRefPubMedPubMedCentral
48.
Scott DT, Lam FY, Ferrell WR: Acute joint inflammation mechanisms and mediators. Gen Pharmacol. 1994, 7: 1285-1296.CrossRef
49.
Schaible HG, Schmidt RF: Effects of an experimental arthritis on the sensory properties of fine articular afferent units. J Neurophysiol. 1985, 54: 1109-1122.PubMed
50.
Schaible H, Grubb BD: Afferent and spinal mechanisms of joint pain. Pain. 1993, 55: 5-54. 10.1016/0304-3959(93)90183-P.CrossRefPubMed
51.
Levine JD, Dardick SJ, Roizen MF, Helms C, Basbaum A: I..Contribution of sensory afferents and sympathetic efferent to joint injury in experimental arthritis. J Neurosci. 1986, 6: 3423-3429.PubMed
52.
Woolf CJ, Salter MW: Neuronal plascity: increasing the gain in pain. Science. 2000, 288: 1765-1768. 10.1126/science.288.5472.1765.CrossRefPubMed
53.
Ewald DA, Sternweis PC, Miller RJ: Guanine nucleotidebinding protein Go-induced coupling of neuropeptide Y receptors to Ca+ + channels in sensory neurons. Proc Natl Acad Sci U S A. 1988, 85: 3633-3637. 10.1073/pnas.85.10.3633.CrossRefPubMedPubMedCentral
54.
Walker MW, Ewald DA, Perney TM, Miller RJ: Neuropeptide Y modulates neurotransmitter release and Ca + + currents in rat sensory neurons. J Neurosci. 1988, 8: 2438-2446.PubMed
55.
Proudfit HK: Pharmacologic evidence for the modulation of nociception by noradrenergic neurons. Pharmacologic Evidence for the Modulation of’ Nociception by Noradrenergic Neurons, Progress in Brain Research, Vol. 77. Edited by: Fields HL, Besson JM. 1988, Amsterdam: Elsevier, 357-370.
56.
Holets VR, Hokfelt T, Rokaeus A, Terenius L, Goldstein M: Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent projections to the spinal cord, cerebral cortex and hypothalamus. Neuroscience. 1988, 24: 893-906. 10.1016/0306-4522(88)90076-0.CrossRefPubMed
57.
Sawchenko PE, Swanson LW, Grzanna R, Howe PR, Howe PR C, Bloom SR, Polak JM: Colocalization of neuropeptide Y immunoreactivity in brainstem catecholaminergic neurons that projects to the paraventricular nucleus of the hypothalamus. J Comp Neurol. 1985, 241: 138-153. 10.1002/cne.902410203.CrossRefPubMed
58.
Illes P, Regenold JT: Interaction between neuropeptide Y and noradrenaline on central catecholamine neurons. Nature. 1990, 344: 62-63. 10.1038/344062a0.CrossRefPubMed
Metadata
Title
Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis
Authors
Lei Wang
Li Zhang
Haobo Pan
Songlin Peng
Minmin Lv
William Weijia Lu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2014
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-15-319

Other articles of this Issue 1/2014

BMC Musculoskeletal Disorders 1/2014 Go to the issue

Research article

Are depression, anxiety and poor mental health risk factors for knee pain? A systematic review

Research article

Bilaterally primary cementless total hip arthroplasty in patients with ankylosing spondylitis

Research article

Evaluation of the measurement properties of the Manchester foot pain and disability index

Research article

Incidence, histopathologic analysis and distribution of tumours of the hand

Study protocol

HUMeral Shaft Fractures: MEasuring Recovery after Operative versus Non-operative Treatment (HUMMER): a multicenter comparative observational study

Research article

Activity levels and participation in physical activities by Korean patients following total knee arthroplasty